Reasons for discontinuation of intravitreal vascular endothelial growth factor inhibitors in neovascular age-related macular degeneration

Retina

Volumn 34, Issue 9, 2014, Pages 1774-1778

  Vaze, Anagha ^a   Fraser Bell, Samantha ^a   Gillies, Mark ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Age related macular degeneration; Patient acceptance; Patient outcomes; Quality of life; Treatment discontinuation; Treatment efficacy; Vascular endothelial growth factor inhibitors

Indexed keywords

RANIBIZUMAB; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; CONTROLLED STUDY; DISEASE SEVERITY; DRUG COST; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PAIN; PATIENT COMPLIANCE; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; REVIEW; ANTAGONISTS AND INHIBITORS; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; PHYSIOLOGY; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; TREATMENT WITHDRAWAL; VERY ELDERLY; VISUAL ACUITY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION; WITHHOLDING TREATMENT;

EID: 84906937069     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000000173     Document Type: Review

References (17)

1. Hampton T. Genetic research provides insights into age-related macular degeneration. JAMA 2010;304:1541-1543.
2. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
3. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116:57-65.e5.
4. Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 2010;94:2-13.
5. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-583.
6. Spielberg L, Leys A. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years. Graefes Arch Clin Exp Ophthalmol 2010;248:943-956.
7. Cohen SY, Dubois L, Tadayoni R, et al. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. Am J Ophthalmol 2009;148: 409-413.
8. Michalova K, Wickremasinghe SS, Tan TH, et al. Ranibizumab treatment for neovascular age-related macular degeneration: from randomized trials to clinical practice. Eye (Lond) 2009;23:1633-1640.
9. Querques G, Azrya S, Martinelli D, et al. Ranibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional setting. Br J Ophthalmol 2010;94:292-296.
10. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-1908.
11. Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012;119:1399-1411.
12. Ehlers JP. The MANTA 1-year results: the anti-VEGF debate continues. Br J Ophthalmol 2013;97:248-250.
13. Chang TS, Bressler NM, Fine JT, et al. Improved visionrelated function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 2007;125:1460-1469.
14. Bressler NM, Chang TS, Suner IJ, et al. Vision-related function after ranibizumab treatment by better-or worse-seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology 2010;117:747-756.e4.
15. Gillies MC, Walton R, Liong J, et al. Efficient capture of highquality data on outcomes of treatment for macular dieases: the fight retinal blindness! project. Retina 2014;34:188-195.
16. Hjelmqvist L, Lindberg C, Kanulf P, et al. One-year outcomes using ranibizumab for neovascular age-related macular degeneration: results of a prospective and retrospective observational multicentre study. J Ophthalmol 2011;2011:405724.
17. Kruger Falk M, Kemp H, Sorensen TL. Four-year treatment results of neovascular age-related macular degeneration with ranibizumab and causes for discontinuation of treatment. Am J Ophthalmol 2013;155:89-95.